Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
HIV infection exerts a negative impact on the course of HCV infection. Co-infected individuals progress more rapidly to liver fibrosis, cirrhosis and ESLD compared to those infected with HCV alone. Some of the this accelerated fibrosis may be related to longterm chronic toxicity from protease inhibitor based ART.
Hypothesis: Switching from ritonavir boosted-PI based ART regimen to a Raltegravir-based regimen will reduce the rate of hepatic fibrosis progression in HIV-HCV co-infected patients as measured by transient elastography (Fibroscan®) and the AST-to-platelet ratio index (APRI).
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Hepatitis C Liver Fibrosis |
Drug: Raltegravir Drug: Ritonavir-boosted protease inhibitor |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomized Prospective Open Label Study of Switching to Raltegravir Based ART Compared to Maintaining Ritonavir Boosted PI-based ART on Liver Fibrosis Progression in HIV-HCV Coinfected Patients |
- To evaluate the effect of switch on change in liver fibrosis score [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Change in fibrosis will be assessed by:
- Change in Fibroscan® score (kPa) at 48 weeks from baseline
- Change in log transformed AST-to-platelt ratio (APRI) score at 48 weeks from baseline
- To evaluate inflammatory markers associated with liver fibrosis [ Time Frame: 72 weeks ] [ Designated as safety issue: No ]As a switch from protease inhibitors based regimen to a raltegravir based regimen may impact the liver through various potential mechanisms, we will explore the impact of treatment switching on inflammatory biomarkers.
- To evaluate effect of switch on hepatic function [ Time Frame: 72 weeks ] [ Designated as safety issue: Yes ]Liver enzymes, albumin, direct bilirubin and INR will be measured at week 0,2,4,8,12,24,36,40 and 72.
- To evaluate effect of switch on metabolic parameters [ Time Frame: 72 weeks ] [ Designated as safety issue: Yes ]Metabolic parameters, such as fasting glucose, lipid and insulin profiles will be measured at week 0,24 and 48 post switch
- Immunologic and virologic safety [ Time Frame: 72 weeks ] [ Designated as safety issue: Yes ]To ensure safety, with respect to control of HIV infection following a switch to raltegravir, HIV viral load and CD4 cell counts will be measured at weeks 0,4,8 12, 24, 36, 48 and 72 post switch.
| Estimated Enrollment: | 40 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: ritonavir-boosted protease inhibitor |
Drug: Raltegravir
Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
Other Names:
Drug: Ritonavir-boosted protease inhibitor
Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
Other Names:
|
| Experimental: Raltegravir |
Drug: Raltegravir
Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
Other Names:
Drug: Ritonavir-boosted protease inhibitor
Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
Other Names:
|
Detailed Description:
Primary Objective-To assess if switching from ritonavir boosted-PI based ART regimen to a Raltegravir-based regimen will reduce the rate of hepatic fibrosis progression in HIV-HCV co-infected patients as measured by transient elastography (Fibroscan®) and the AST-to-platelet ratio index (APRI) after 48 weeks of treatment.
Secondary Objectives:
(i) To assess the safety and tolerability of switching from a ritonavir boosted-PI ART regimen to a raltegravir-based regimen for 48 weeks.
(ii) To evaluate hepatic function (liver enzymes) at weeks 0, 2, 4, 8, 12, 24, 36, 48 and 72 post switch.
(iii) To evaluate the effect of switching treatment on control of HIV infection (as measured by HIV viral load and CD4) at weeks 0, 4, 8, 12, 24, 36, 48, and 72 post switch.
(iv) To evaluate metabolic profiles (e.g, fasting lipid profiles, glucose and insulin) at weeks 0, 24, 48 and 72 post switch.
(v) To evaluate inflammatory markers associated with liver fibrosis at weeks 0, 2, 4, 8, 12, 24, 36, 48 and 72 post switch.
Population: Patients will be selected from CTN222; a Canadian National multisite prospective cohort of HCV-HIV infected persons (N=978) or from other eligible patients followed at participating sites. All patients recruited into the cohort are adults aged over 16 years old with documented HIV infection (ELISA with western blot confirmation) and with chronic HCV infection or evidence of HCV exposure (e.g. HCV-seropositive by ELISA with RIBA II or EIA confirmation, or if serologically false negative, HCV RNA+).
Study Design: A Randomized Prospective Open label study
Sample Size:
N = 40 This is a Phase II study designed to evaluate the safety and feasibility of a switch to raltegravir in HIV-HCV co-infected patients. As neither the duration of time required to improve fibrosis nor the potential impact of such a switch currently is known, this trial will provide important pilot data with which to estimate the true effect size and calculate the sample size required to conduct a larger definitive study on this question. It is hypothesized that switching therapy will lead to significant reduction in fibrosis as measured by APRI and FibroScan®. In other studies, for example, of successful HCV treatment using FibroScan®, a 34% reduction in fibrosis score was observed in those obtaining a sustained virologic response at 48 weeks (e.g., from mean baseline score of 10.3 kPa to 6.6 kPa at 48 weeks; s.d.= 5 kPa 1). We propose a sample size of 20 patients in each group, which would provide approximately 80% power to detect at least a difference of 5 kPa in fibrosis score change between the two groups assuming a similar standard deviation.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years or older
- Chronic HIV-HCV co-infection (HCV RNA + for at least 6 months and could have had previous HCV treatment).
- Receiving ritonavir boosted PI-based ART for at least 6 months.
- APRI score ≥ 1.5 (equivalent to liver biopsy score of ≥ F2) AND/OR Fibroscan > 6.9KPa
- HIV viral suppression (<50 copies/mL) for at least 6 months.
- No prior evidence of resistance to raltegravir or co-administered nucleoside backbone.
- No prior history of virologic failure.
Exclusion Criteria:
- Clinical evidence of decompensated liver disease (e.g., ascites, esophageal varices, or hepatic encephalopathy hepatoma or hepatocellular carcinoma).
- Chronic Hepatitis B infection (defined as positive HBsAg or Hepatitis B viral load greater than 10,000 copies/mL).
- AFP greater than or equal to 200 ng/mL at screening.
- Known or suspected Wilson's disease, alpha-1-antitrypsin deficiency, celiac disease or other cause of chronic liver disease.
- Chronic renal insufficiency (eGFR < 20 mL/min) at screening.
- Pregnancy and planned pregnancy (WOCBP not using adequate contraception).
- Women who are breastfeeding.
- Active opportunistic infection (except oral thrush) or neoplasm (except Kaposi's sarcoma, skin cancer, or cancer of the cervix or anus, unless known or suspected liver metastasis).
- Patients intending to start HCV therapy within the treatment phase (within the year following the baseline visit).
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01231685
| Canada, British Columbia | |
| Providence Health Care- St. Paul's Hospital | |
| Vancouver, British Columbia, Canada, V6Z 1Y6 | |
| Canada, Ontario | |
| University Health Network - Toronto General Hospital Division | |
| Toronto, Ontario, Canada, M5G2N2 | |
| Canada, Quebec | |
| Montreal Chest Institute | |
| Montreal, Quebec, Canada | |
| Principal Investigator: | Marina B Klein, MD. M.Sc. | McGill University Health Center |
More Information
Publications:
| Responsible Party: | Marina Klein, MD, McGill University Health Center |
| ClinicalTrials.gov Identifier: | NCT01231685 History of Changes |
| Other Study ID Numbers: | CTN260 |
| Study First Received: | October 29, 2010 |
| Last Updated: | January 13, 2015 |
| Health Authority: | Canada: Health Canada |
Keywords provided by McGill University Health Center:
|
Liver fibrosis HIV Hepatitis C Virus Coinfection |
Additional relevant MeSH terms:
|
Fibrosis Hepatitis C Liver Cirrhosis Digestive System Diseases Flaviviridae Infections Hepatitis Hepatitis, Viral, Human Liver Diseases Pathologic Processes RNA Virus Infections Virus Diseases |
HIV Protease Inhibitors Protease Inhibitors Ritonavir Anti-HIV Agents Anti-Infective Agents Anti-Retroviral Agents Antiviral Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Therapeutic Uses |
ClinicalTrials.gov processed this record on March 03, 2015